• Explore /
  • Poster
  • / Neoadjuvant combination immunotherapy with pembrolizumab and high dose IFN-α2b in locally/regionally advanced melanoma.

Neoadjuvant combination immunotherapy with pembrolizumab and high dose IFN-α2b in locally/regionally advanced melanoma.

Abstract Poster

Authors

Ahmad Tarhini

Ahmad A. Tarhini

Case Comprehensive Cancer Center / Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Ahmad A. Tarhini, Yan Lin, Joseph J. Drabick, Rogerio Izar Neves, Marc S. Ernstoff, Igor Puzanov, Priyanka Vallabhaneni, James F. Pingpank, Matthew Peter Holtzman, Cindy Sander, John M. Kirkwood

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies

Sub Track

Biomarkers and Inflammatory Signatures

Clinical Trial Registration Number

NCT02339324

Citation

J Clin Oncol 36, 2018 (suppl 5S; abstr 181)

DOI

10.1200/JCO.2018.36.5_suppl.181

Abstract #

181

Poster Bd #

H8

Abstract Disclosures

Similar Posters

Poster

2019 ASCO Annual Meeting

A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma.

A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma.

First Author: Yana Najjar

First Author: Ahmad A. Tarhini

First Author: Dara Mark Bracken-Clarke

First Author: Sakti Chakrabarti